INTRODUCTION
Subclinical gut inflammation has been described in up to 60% of patients with spondyloarthritis (SpA) [1] , with up to 10% of those with more pronounced gut inflammation evolving in a clinically overt Crohn's disease [2] . On the basis of these epidemiologic findings, SpA-associated gut inflammation has been initially thought as a preclinical model of Crohn's disease where to study early immunological alterations related to Crohn's disease. This point of view, however, seems to be too simplistic since a growing body of recent evidence suggest that gut inflammation, at least in ankylosing spondylitis (AS) patients, is not an epiphenomenon of the ongoing systemic inflammatory process but rather an important etiological event that may actively participate in the pathogenesis of AS. This article will focus on recent studies regarding the innate and adaptive immune responses occurring in the inflamed gut of AS patients.
TEXT OF REVIEW

Histology
Two main types of gut inflammation have been described in AS patients: acute inflammation, resembling a self-limiting bacterial enterocolitis, and chronic inflammation, displaying altered intestinal architecture with strong infiltration of mononuclear cells eventually aggregated in lymphoid follicles, resembling the ileocolitis seen in Crohn's disease [1] . Behind the architectural alterations described in AS gut, other histologic findings seem to characterize the inflamed ileum of AS. Relevant epithelial alterations are in fact present in AS gut, mainly characterized by goblet cells hyperplasia (with increased mucins production) [3] and activation of paneth cells, producing high levels of antimicrobial peptides [4] and proinflammatory cytokines such as IL-23 [5] . Other histologic alterations include the presence of detachment of epithelial cells from the basal membrane and the occurrence of vasculitic lesion, mainly represented by intense hemorrhagic extravasation in the context of lamina propria (Fig. 1) [6] . Although we cannot exclude that genetic factors may be responsible for these alterations, similar epithelial damages have been described as a consequence of the response of epithelial cells to bacterial toxins [7, 8] .
Intestinal dysbiosis in ankylosing spondylitis
Crohn's disease is one of the major inflammatory bowel diseases. Genetic studies have demonstrated that several genes, most of which were involved in immune responses, appear to predispose for Crohn's disease [9] . However, genes alone cannot explain the pathogenesis of Crohn's disease. Increasing evidence suggests that the intestinal microbiota may play a role in initiating and maintaining the phenotype of Crohn's disease. A number of studies have
KEY POINTS
Intestinal dysbiosis occurs in AS.
The inflamed gut of AS is the main site of production of IL-23.
Activation and expansion of ILCs occur in the gut of AS.
Gut-derived ILCs accumulate in the site of inflammation in AS. in fact demonstrated the presence of significant alteration in Crohn's disease gut microbiome mainly characterized by the occurrence of opportunistic pathogens, the presence of dysbiosis, the presence of functional alterations in the commensal bacteria, and the host inability in containing commensal microorganisms probably because of genetic factors (reviewed in [10] ). The resulting continuous antigenic stimulation may activate pathogenic T effector cells that may be in turn responsible of the chronic intestinal inflammation. Human leukocyte antigen B27 (HLA-B27) is a major risk factor for AS [11] . The role of HLA-B27 in shaping the gut microbiome has been studied by the Rosenbaum's group demonstrating, by using biome representational in-situ karyotyping and 16S ribosomal ribonucleic acid gene sequencing, that Lewis rats transgenic for HLA-B27 and human b2-microglobulin, had significant differences in the cecal microbiota compared with wild-type Lewis rats [12] . The role of gut microbiome in AS pathogenesis is also suggested by many studies [13] [14] [15] that demonstrate, in patients and first-degree relatives, an increased intestinal permeability. In this regard, it is probable that AS may be triggered by common environmental (microbial) agents in genetically susceptible individuals. Costello et al. [16 && ] recently performed culture-independent microbial community profiling of terminal ileum biopsy specimens from AS patients and healthy controls to characterize and investigate any differences in the gut microbiome. Terminal ileal biopsies obtained from AS patients were analyzed for their microbial profiles. Ileal microbial communities of patients with AS differed significantly from healthy controls, being characterized by higher abundance of five bacteria families: Lachnospiraceae, Veillonellaceae, Prevotellaceae, Porphyromonadaceae, and Bacteroidaceae.
The evidence of altered microbiome in other SpA phenotypes reinforces the role of intestinal dysbiosis in this group of related disorders. Altered microbiota, characterized by reduced Faecalibacterium prausnitzii and Lachnospiraceae families and an increase in Bifidobacterium, has been recently demonstrated in enthesitis-related arthritis associated with an abnormal humoral immune response [17] . Furthermore, patients with psoriatic arthritis had a lower relative abundance of multiple intestinal bacteria displaying a microbiota profile similar to that previously described in patients with inflammatory bowel disease and associated with changes in specific inflammatory proteins [18] . Although the findings coming from these works, are interesting studies are needed to specifically address the effect of intestinal dysbiosis on innate immune responses and tissue inflammation and to value if the changes in intestinal microbial composition are because of host genetics.
Macrophage signature in ankylosing spondylitis gut
As the dysbiosis observed in AS, it is likely that host factors, such as cells of the innate immune system, may predispose for the establishment of an altered intestinal microbiome. Intestinal macrophages are important components of intestinal immunity and essential for the maintenance of mucosal homeostasis [19] . Intestinal macrophages are unresponsive to bacterial stimuli, displaying a reduced expression of Toll-like receptors (TLRs) and other functional receptors necessary for macrophage activation (i.e. CD14) [20] . In Crohn's disease, this anergic phenotype is lost and CD14-expressing macrophages accumulate in the inflamed lamina propria where they release proinflammatory mediators and are involved in the induction of Th1 and Th17 responses [21, 22] .
Macrophages are not a homogeneous population and, according to their phenotype and function, different pathways of macrophage activation have been described in humans. Following the Th1/ Th2 nomenclature, macrophages are subdivided in prevalent M1 (classical/proinflammatory) or M2 (alternative/antiinflammatory) types, representing, however, the extremes of a continuum of activation states [23] . Another subset of macrophages, possessing aspects of both definitions consistent with an immune regulatory phenotype, the so-called resolution phase macrophages (rMs) has been recently described [24] . Impairment of M1-derived mediators and expansion of M2 macrophages have been demonstrated in the colon and synovial fluid of AS patients [25, 26] . Interestingly, in the AS facet joints IL-23 seems to be predominantly produced by M2 but not M1 macrophages [27] . In the ileum of AS patients, balanced macrophage activation seems to be present with CD14 þ macrophages being virtually absent and classically activated M1 macrophages (iNOS þ IL-10 -CXCL-9 þ ) expanded. Furthermore, a significant increase of iNOS þ IL-10 þ cells (defined as rMs) and CD163 þ ileal macrophages (M2 macrophages), strictly correlated with the expression of IL-33, a Th2 cytokine involved in M2 polarization, is also present in AS gut [28] . Expansion of rMs and of M2 macrophages, incompetent to eradicate intestinal bacteria, may be responsible for the persistence of intestinal dysbiosis and for lack of excessive local inflammation observed in the ileum of AS patients. The aberrant production of IL-23 by M2 macrophages, described in the spine of AS patients, and their specific role in modulating innate and adaptive immune responses need to be better investigated.
Immunologic signature of ankylosing spondylitis gut
According to M1 deficient polarization, an impaired Th1 profile with a possible Th2 polarization has been reported in gut lamina propria lymphocytes from patients with AS [5, 29] . Immunologically, however, the gut of AS seems to be more complexly signed. IL-23 in particular has recently emerged as a key cytokine involved in the regulation of innate and adaptive immune responses in AS [30] . IL-23 mainly acts as a regulator of the maturation of autoreactive T cells producing IL-17 (Th17), and promotes chronic inflammation dominated by IL-17, IL-6, IL-8, and TNF-a, as well as by neutrophils and macrophages [31] .
Although in Crohn's disease patients, the IL-17/ IL-23 axis has been proved to be particularly activated, targeting Th17 responses via secukinumab (anti-IL-17A) resulted in worse outcomes [32] . The apparently paradoxical effect of IL-17 blocking agents may suggest critical differences between IL-17 itself (mainly produced by cells of the innate immune system), possibly involved in tissue protective responses, and the highly pathogenic Th17 cells. However, we cannot exclude that activation of different immune pathways following IL-17 inhibition, such as Th1 or Th22 cells, and/or modifications in the intestinal microbiome induced by loss of control by IL-17, may also be responsible for the failure of anti-IL-17 therapy.
Behind the role of IL-23 in the modulation of the Th17 pathway, recent reports identify an important role for IL-23 in directly modulating the innate intestinal immune system by activating and expanding the so-called innate lymphoid cells (ILCs) of type 3 [33 && ,34] . IL-23 upregulation is present in the terminal ileum of AS patients, mainly in the context of paneth cells, and is not accompanied by a clear Th17 polarization [5] indicating a role of this proinflammatory cytokine in directly driving intestinal immune responses.
Although the regulation of IL-23 in AS gut is not completely understood, a pathway of innate immune system (the so-called macroautophagy or autophagy) may be implicated in IL-23 modulation [35] . Autophagy is a basic cellular machinery responsible in eukaryotic cells for bulk degradation of cellular constituents to provide energy resources to the cells, also acting by directly eliminating intracellular microbes or their products [36] . Another function of autophagy is connected to its ability to target improperly folded proteins for degradation in close connection with the endoplasmic reticulum (ER) stress response known as the unfolded protein response (UPR) [37] . Autophagy seems to be differentially regulated in the gut of AS patients where a strong and significant upregulation of autophagy-related 16-like 1 (ATG16L1), immunity-related GTPase family M protein (IRGM), and microtubule-associated proteins 1A/1B light chain 3A (MAP1LC3A) together with a decreased expression of genes involved in the so-called chaperonemediated autophagy occur. In particular, expression levels of ATG16L1, IRGM, and MAP1LC3A seem to be correlated with IL-23p19 in AS patients with chronic gut inflammation and inhibition of autophagy and chaperone-mediated autophagy appears sufficient, in the presence of lipopolysaccharide, to reduce the percentage of IL-23 expressing cells at the same time increasing the mRNA levels for IL23p19 in the lamina propria mononuclear cells (LPMCs) [38 && ]. Although activation of autophagy has not been demonstrated in the peripheral blood and synovial tissues of AS [39] , our findings seem to indicate this pathway as one of the potential immunological factors regulating the production and secretion of IL-23 in AS in the gut.
Although these findings are of interest, linking bacterial innate immune responses to IL-23 production, other pathways might be implicated in the production of IL-23. In this regard, UPR as a consequence of HLA-B27 misfolding has been proposed, in murine models of AS, as a main pathway involved in IL-23 production [40] . This model, however, has not been confirmed in humans where UPR seems to be not significantly modulated [41] . Interestingly, free heavy chain misfolding occurs in the gut of AS patients without any increased expression levels of UPR genes, indicating that probably UPR in human gut is strictly modulated by other immunological pathways [38 && ]. In this regard, our data indicate that inhibition of autophagy and chaperone-mediated autophagy increases in AS LPMCs the levels of misfolded heavy chains and a clear upregulation of UPR genes [42] . As our results support the presence of HLA-B27 misfolding, we cannot obviously exclude that ER stress caused by HLA-B27 in the gut of AS patients may contribute to the intense activation of autophagy, which in turn may further limit the full UPR activation by enhancing the removal of misfolded protein.
Innate immune responses in ankylosing spondylitis gut
The role of IL-23p19 in driving AS pathogenesis seems to be linked to its ability in modulating IL-17 and IL-22 production, two cytokines actually considered important actors in driving spinal inflammation and osteoproliferation [43] . IL-23-responsive entheseal resident T cells producing IL-17 and IL-22 have been observed in a murine model of AS and correlated to AS pathogenesis [43] . The exact nature of these cells and their developmental origin remain elusive, also sharing immunological similarities with specific subsets of ILCs.
ILC populations are specialized effector cells involved in the regulation of innate immunity and inflammation through the secretion of specific cytokines and chemokines. ILCs are characterized by the absence of recombined antigen-specific receptors, the absence of specific markers associated with other immune cell lineages and a lymphoid morphology [44] . Based on their cytokine repertoire, ILCs are classified into three groups (ILC1, ILC2, and ILC3): ILC1s express the transcription factor T-bet, produce IFN-g, and mediate immunity against intracellular pathogens and tumors; ILC2s produce IL-5 and IL-13; ILC3s are an important source of IL-22 and IL-17, in response to IL-23, express the retinoic acid, ROR-g, and are required for mediating immunity to extracellular bacterial infections, also providing help to marginal zone B cells, and may also play a proinflammatory role [45, 46] . ILC3s seem to be essentially mucosalrestricted cells, developmentally related to lymphoid tissue-induced cells (LTi) and dependent on IL-7 for their differentiation [40] . These ROR-g þ cells are essentially involved in protective response by negatively regulating Th17 cells through the modulation of intestinal microflora [47,48 && ]. ILC3 may be further subdivided according to whether they express natural cytotoxicity receptors, such as the NKp44 receptor. Although the ligand for NKp44 in normal tissues has not yet been identified, it seems to bind to an unusual isoform of the mixed lineage leukemia 5 protein [49] and the continued engagement of NKp44 and cytokine receptors may induce a potent proinflammatory program in NKp44 þ ILC3 cells [50] . Specifically in the gut of patients with AS, ILC3 expressing the natural cytotoxicity receptor NKp44 are significantly expanded and possibly involved in tissue protective mechanisms [3] .
ILC populations were recently studied in the gut of AS patients [51 && ] . No significant expansion of ILC1 and/or ILC2 was observed. Conversely, a consistent expansion of NKp44
was demonstrated in patients with AS with acute and chronic gut inflammation significantly correlated with the disease activity as assessed by the Bath Ankylosing Spondylitis Disease Activity Index. Type 3 ILCs were also expanded in the gut, in the peripheral blood, in the synovial fluid and in the bone marrow of patients with AS and express the homing integrin a4b7. In addition, mucosal vascular addressin cell adhesion molecule 1, the a4b7 ligand, was found to be highly represented in the high endothelial venules of the gut and in the inflamed bone marrow of AS, suggesting a role for this receptor in chemoattracting ILC3 at the site of active AS inflammation and a recirculation of ILC3 between the gut and the bone marrow (Fig. 2) . In this regard, a better definition of the role of M2 macrophages in regulating ILC3 (for example, through the production of IL-23) needs to be defined.
ILC3s are developmentally related to LTi cells [47] . Aggregates of LTi in the small intestine of patients with AS were observed in close proximity to intestinal crypts [51 && ]. These structures, highly suggestive for cryptopatches, have been hypothesized to be sites of active postnatal extrathymic T cell development (as a consequence of intestinal bacteria colonization) and demonstrated only in the colon in humans [52, 53] . Aggregates of c-kit
-cells were, however, demonstrated in the ileum of AS patients, in close proximity to intestinal crypts. In the gut of AS, paneth cells express IL-7 and coculture of LTi with epithelial cells isolated from patients with AS strongly induces the differentiation of ILC3, also increasing the expression of IL-17 and IL-22 [51 && ]. These results suggest a pivotal role of paneth cells in activating and amplifying intestinal innate immune responses in the gut of patients with AS resulting in active ILC3 differentiation (Fig. 2) .
Clinical associations between axial and subclinical gut inflammation in ankylosing spondylitis
Bone marrow edema (BME) of the sacroiliac joints (SIJs) is actually considered to be a hallmark of axial SpA. A recently published study [54 && ] specifically assessed the link between BME of the SIJs and gut inflammation and the correlation between BME and established disease activity parameters. The study was performed on 68 patients with axial SpA from the Gent Inflammatory Arthritis and spoNdylitis cohorT underwent ileocolonoscopy and MRI of the SIJs. Histopathological analysis and SPondyloArthritis Research Consortium of Canada (SPARCC) scores were performed. In this study, a significantly higher SPARCC score was observed in axial SpA patients showing chronic gut inflammation compared with axial SpA patients showing normal gut histology. By using a multiple linear regression model, the authors identified chronic gut inflammation to be independently associated with the extent of BME indicating a link between mucosal inflammation and axial disease in SpA.
Murine models of gut inflammation in ankylosing spondylitis
To study how host genetics may influence gut microbiota and the eventual relationship between microbiota and organ inflammation in SpA, Rehaume and coworkers [55] studied BALB/c ZAP-70(W163C)-mutant (SKG) mice, TLR-4-deficient SKG mice, and wild-type BALB/c mice maintained under germ-free conditions, and recolonized with altered Schaedler flora. The mice were injected intraperitoneally with microbial b-1,3-glucan (curdlan) and arthritis, spondylitis, and ileitis assessed histologically. Microbiota content and response to curdlan varied according to whether T cell receptor signal strength was normal or was impaired because of the ZAP-70(W163C) mutation. Curdlan triggered acute inflammation regardless of the presence of the SKG allele or microbiota. However, no or limited microbiota content attenuated the severity of arthritis. In contrast, ileal IL-23 expression, ER stress, lymph node IL-17A production, goblet cell loss, and ileitis development were microbiota dependent. Ileitis but not arthritis was suppressed by microbiota transfer upon cohousing SKG mice with wild-type BALB/c mice, as well as by TLR-4 deficiency. The effects of IL-23 and IL-22 inhibition in IL-17A(À/À) in curdlan-treated SKG or BALB/c mice were assessed in another study [56] . In curdlan-treated SKG mice, arthritis, enthesitis, and ileitis were IL-23 dependent and enthesitis was specifically dependent on IL-17A and IL-22. IL-23 was induced in the ileum, where it amplified ER stress, goblet cell dysfunction, and proinflammatory cytokine production. IL-17A was pathogenic, whereas IL-22 was protective against ileitis. IL-22 þ CD3 -innate-like cells were increased in LPMCs of ileitis-resistant BALB/c mice, which developed ileitis after curdlan injection and anti-IL-22.
CONCLUSION
Subclinical gut inflammation may be the hidden place where, because of the continuous stimulation of the immune system by an altered microbiome, a chronic activation of the innate immune system occurs. In particular, ILCs activated in the gut may accumulate in the inflammatory lesions of patients with AS, potentially being a relevant early source of AS-associated effector cytokines and important drivers of mucosal and systemic inflammation. Insights into how modulation of ILCs for therapeutic purposes might affect the clinical outcome in AS patients are strongly awaited.
